RxDoctor Payments Data

Randy Jordan, MD

Interventional Cardiology · Little Rock, ARNPI 1780695312

Payments from drug & device makers

$3,637in general payments, 2019–2025

Across 256 payments — averaging $14.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Boehringer Ingelheim$335
  • Pfizer$274
  • Johnson & Johnson$236
  • Amgen$210
  • Sanofi-aventis U.S. LLC$190
  • plus $823 from 18 others

What the payments were for

  • Food & beverage$3,632100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,637 in reported general payments places this provider in the 25th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$63,135
Medicare patients
544
Services billed
1,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban506$398,084
EntrestoSacubitril/Valsartan297$253,796
XareltoRivaroxaban101$76,970
JardianceEmpagliflozin95$72,022
FarxigaDapagliflozin Propanediol34$24,016
Repatha SureclickEvolocumab26$22,085
NexlizetBempedoic Acid/Ezetimibe11$9,280
Metoprolol Succinate379$7,649
Atorvastatin Calcium428$4,140
Ranolazine ErRanolazine34$4,075
Losartan Potassium295$2,854
Carvedilol256$2,513
Rosuvastatin Calcium111$1,804
Clonidine13$1,759
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide60$1,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$274$398,084506 claims
NovartisEntresto$1,568$253,796297 claims
Johnson & JohnsonXarelto$236$76,970101 claims
Boehringer IngelheimJardiance$335$72,02295 claims
AstraZenecaFarxiga$141$24,01634 claims
Esperion Therapeutics, Inc.Nexlizet$30$9,28011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →